Article Information
History
- July 23, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Arya Sheela Nair1,#,
- John Woodford1,2,#,
- Jessica Loughland1,6,
- Dean Andrew1,
- Kim Piera3,
- Fiona Amante1,
- Timothy William4,
- Matthew J Grigg3,
- James S McCarthy1,5,
- Nicholas M Anstey3,
- Michelle J Boyle1,6 and
- Bridget E Barber1,3,*
- 1QIMR Berghofer Medical Research Institute, Brisbane, Australia
- 2Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Bethesda, United States
- 3Menzies School of Health Research, Darwin, Australia
- 4Subang Jaya Medical Centre, Selangor, Malaysia
- 5Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
- 6Burnet Institute, Melbourne, Australia
- ↵*Corresponding author, bridget.barber{at}qimrberghofer.edu.au
↵# these authors contributed equally.
Posted July 23, 2024.
Osteoprotegerin (OPG) and its ligands RANKL and TRAIL in falciparum, vivax and knowlesi malaria: correlations with disease severity, and B cell production of OPG
